Glucagon antagonists/inverse agonists
US6562807B2 · kind B2 · utility
13Cited by
6References
70Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2001 |
| Grant date | May 13, 2003 |
| Priority date | — |
| Expiry date | Jun 22, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/16
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.